Having listening to the CC, I'm out of there with a clear conclusion: The PPPS division is worth much, much, much more than the 3$ we've been talking about! :-) We already knew that CNBG will bring in about 22-24M$ gross margin. Octopharma about 15$. Let me guess Nant brings in as much as CNBG, and Novozyme and Halozyme each as much as Octopharma. Say that's a total of about 90M$ of ...

and on track:Revenues of $4.4 million in Q1 2013, an increase of $3.3 million compared to Q1 2012Revenues expected to exceed $11.0 million by the end of June 2013, compared to $7.4 million for the first half of 20122013 revenues expected to significantly exceed 2012 revenuesIND for PBI-4050 expected to be filed in Q3 2013ProMetic BioProduction's plasma purification and manufacturing facility ...

revenue jump again: ProMetic Reports Highlights of Its 2012 Annual and Special Meeting of Shareholders and Its First Quarter 2013 Financials Results- Revenues of $4.4 million in Q1 2013, an increase of $3.3 million compared to Q1 2012 - Revenues expected to exceed $11.0 million by the end of June 2013, compared to $7.4 million for the first half of 2012 - 2013 revenues expected to significantl ...

PROMETIC AND SARTORIUS STEDIM BIOTECH (“SSB”) JOIN FORCES TO PROMOTE NOVEL TURNKEY SOLUTION FOR PRODUCING PLASMA-DERIVED THERAPEUTICSProMetic BioProduction's plasma purification facility to become the technological showroom for Plasma Protein Purification System ("PPPSTM") SSB to contribute equipment and consumables ProMetic and SSB to co-market PPPSTM on a global basi ...

I couldn't agree more, mtnbkr. The main risk facing PLI at this juncture is 'execution risk' and frankly that is relatively small. In the protein division, revenue capacity of PLI's two manufacturing plants ($150M - Laval for PPPS; $100M Isle of Mann for resin) amounts to $250M/year which easily supports an sp of $3/share! What people don't seem to understand is that the par ...